Micregen strengthens leadership with Graeme Bell as first Independent, Non-Executive Director

With a 30-year record of accomplishment working with some of the world's most recognised names in the life sciences sector, Graeme Bell has been appointed as Micregen's leading financial expert, serving as an independent member to Board of Directors.

Reading, United Kingdom - May 7 - Micregen, an award-winning biotech company and a pioneer in increasing health span and prolonging the period of high-quality active life, is pleased to announce the appointment of Graeme Bell as its first Independent, Non-Executive Director (Finance). He's played a key role in building and scaling platform-based biotech companies across both private and public markets.

A seasoned leader in biotechnology, financial strategy, governance and corporate growth, Bell has taken on this new role to lead Micregen's investment strategy and help guide the company through its next phase of growth. With over 30 years in leadership roles across the biotech industry including serving as Chief Financial Officer roles at Valo Health, Tmunity, Anacor Pharmaceuticals, Intellia Therapeutics and Merck, Sharpe & Dohme and co-lead raising over $1.5 billion for emerging-growth biotech companies, he brings deep experience in financial strategy, compliance and governance at public and private enterprises.

Micregen has made significant advancements in its journey to date to bring innovative therapeutics to market. "Over the past six months, the company has implemented a lean operating model and strategically restructured the Board to enhance operational focus and decision-making agility," Graeme Bell explains. "While bringing in new directors with specialized expertise, we've maintained our founding scientists as trusted advisors to preserve the institutional knowledge driving our innovation."

"We are delighted to welcome Graeme to Micregen's Board of Directors. He has both breadth and depth of experience in corporate finance and a distinguished record as both a public and private Chief Financial Officer in the biopharmaceutical sector," comments Dr Athanasios Papadopoulos, Executive Chairman of Micregen. "Micregen will benefit greatly from his experience and leadership as we continue to secure the capital needed to advance our groundbreaking investigational programs toward the clinic and bring our innovative therapies to patients. We welcome Graeme and look forward to his contributions."

"I am excited to join the Micregen Board of Directors at such an exciting time for the company, as Micregen declares its first drug candidate and will soon evolve into a clinical-stage company," Graeme Bell continues. "In pioneering a new approach to tackle critical disease challenges, Micregen's secretome based technology is unique and potentially transformative, utilising an industry-leading platform that generates allogeneic stem cell derived, though cell-free, therapeutic candidates.

"I look forward to joining my fellow Directors and the management team in helping the company realise the full potential and promise of what I believe can be life-changing therapies for patients living with devastating degenerative diseases."

As founder of Value Cycle, Graeme Bell brings to the Micregen Board three decades of executive experience and leadership skills. He currently serves as advisor to several private, emerging biopharma and tech companies and was also previously the interim President, Chief Executive Officer of Valo Health as well as serving as a former Executive Vice President and Chief Financial Officer. Prior to working at Valo, Graeme Bell served as CFO at Tmunity and, previous to that, he was CFO at Intellia Therapeutics, CFO at Anacor. He spent more than 20 years in roles of increasing responsibility, culminating as U.S. CFO at Merck & Co., Inc.

Graeme Bell received his professional qualifications from the Chartered Institute of Management Accountants (FCMA), and has an MBA from Durham University, England. His recent awards include being names as 2023 CFO of the Year by Boston Business Journal.

He took up his new position last month and concludes: "What attracted me to Micregen is its pioneering science and exceptional team. The progress achieved by the company's ongoing support and under £10 million investment to date demonstrates remarkable efficiency and potential. My immediate focus will be further aligning our financing strategy with planned scientific objectives to ensure Micregen is well positioned for future fundraising and returning value to shareholders."

Micregen, The Gateway, 1 Collegiate Square, Thames Valley Science Park, Reading, Berkshire, RG2 9LH, United Kingdom.

For media inquiries and further information, please contact stephensharp@micregen.com Find out more online at www.micregen.com

Micregen is a biotech company headquartered in Cheshire, United Kingdom. It was founded in 2015 by Dr Steve Ray, a stem cell therapy expert and one of his patients, Barry Sharples, a serial entrepreneur. Their shared vision is to increase health span and prolong the period of high-quality active life for everyone. Micregen aims to achieve this through its proprietary platform technology, developed from a deep understanding of how stem cells can be manipulated to produce potent stem cell secretome, known as Secretomix®. Secretome products have been proven to facilitate tissue repair, modulate inflammation and scarring, activate resident stem cells, improve blood flow, and produce a pro-regenerative microenvironment across a wide range of organs and tissue types, presenting the possibility for Secretomix® therapeutics to ultimately target all the root causes of ageing as opposed to individual symptoms.

Micregen have close collaborations with global Key Opinion Leaders in various diseases from renowned universities and hospitals in the UK, USA, and Canada. In September 2023, the Secretomix® platform won the 2023 UK Pharma Industry Awards, Innovation of the Year. This acknowledgement follows a notable milestone in January 2023, when Micregen was invited to join the UK Research and Innovation (UKRI) Scale-Up Program reserved for innovative companies disrupting their industries with high potential for exponential growth and internationalisation. UKRI have also awarded Micregen three separate grants, including a SMART Award. Micregen also received an invitation to participate in the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) ILAP program, designed to expedite the entry of innovative therapeutics into the market in December 2022.
Micregen's scientific team boasts a cumulative experience of over 100 years in stem cell research. Their significant contributions to regenerative medicine are evident in the publication of hundreds of peer-reviewed papers over the last 30 years.
Micregen is managed by commercial experts who have led IPOs, business sales and multi-billion-dollar transactions in the life science industry. The company has raised nearly £9 million in funding to date. Careful use of funds and strong academic, clinical, and industry support has allowed Micregen to develop and optimise the Secretomix® platform and progress to the manufacture of its first clinical-grade product. Micregen Co-Founder Prof. Paolo De Coppi Included in TIME Magazine's 100 Most Influential People in Health 2024.

This release was published on openPR.